In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection
Abstract COVID-19 has currently become the biggest challenge in the world. There is still no specific medicine for COVID-19, which leaves a critical gap for the identification of new drug candidates for the disease. Recent studies have reported that the small-molecule enoxacin exerts an antiviral ac...
Guardado en:
Autores principales: | Amirhossein Ahmadi, Sharif Moradi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5ca25b6c50e4471d8b5bd1556e481349 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
por: Ying Li Weng, et al.
Publicado: (2021) -
Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
por: Katarzyna Papaj, et al.
Publicado: (2021) -
C60 fullerene against SARS-CoV-2 coronavirus: an in silico insight
por: Vasyl V. Hurmach, et al.
Publicado: (2021) -
Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing [version 2; peer review: 2 approved]
por: Fabiola E Tristán-Flores, et al.
Publicado: (2021) -
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.
por: Agnieszka M Szemiel, et al.
Publicado: (2021)